Oncology

Explore the role of primary antibodies targeting CD proteins in neurobiology and cancer research. Read more to discover how these antibodies facilitate precise cell population identification in the nervous system and contribute to human cancer disease diagnosis and prognosis.

Explore the importance of new biomarkers in glioma research and their potential to revolutionize diagnosis, prognosis, and treatment of this aggressive brain tumor. Discover new emerging biomarkers that will help to enhance patient outcomes and guide personalized therapeutic strategies.

A neuroendocrine neoplasm (NEN) begins in the cells of the neuroendocrine system. These cells have traits of both hormone-producing endocrine cells and nerve cells. The advent of second-generation NEN markers for use in immunohistochemistry has considerably expanded the pathology toolbox for diagnosing and classifying NENs. Atlas Antibodies has released new monoclonal markers targeting NENs. Read more in our new blog post!

In our new ”Interview with a Scientist” blog post, we asked Antonio Marzio, Ph.D., about his research on the mechanisms that drive immune-resistant responses in patients with non-small-cell lung carcinoma (NSCLC). Read on to learn more!

Our new Research Roundup summarises three cancer research studies that have used polyclonal antibodies from Atlas Antibodies. Today we share insights into a new biomarker for glioma, the metastatic process in colorectal cancer, and the effect of ginseng metabolites on cancer cells proliferation. Learn more!

T-Cell receptors therapy is a growing area of immuno-oncology with recent breakthroughs in clinical settings, thereby demonstrating his therapeutic potential in mitigating tumor development. So what do you know about T-Cell therapy? Read on! Dr. Erika von Euw from T-Cure Bioscience help us to understand it better.

In this blog post, we share bits of evidence about the involvement of voltage-gated ion channels in human cancers, highlighting their promising use as biomarkers. Read on!

Are you interested in seeing more of our antibodies in action? The following three studies have successfully utilized our antibodies to suggest or identify new biomarkers for different human cancers. Keep reading.

Many of our cancer antibodies are used in cutting-edge research to identify new prognostic markers in different cancers. Let's take a look at three recent studies.

Drug repurposing is the strategy of using existing drugs originally developed for a specific disease to treat other diseases. We have interviewed Dr. Joanna Zawacka-Pankau about her research in drug repurposing to treat cancer.